Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Long-Term Deferred Tax (2016 - 2019)

Niagen Bioscience (NAGE) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $218000.0 as the latest value for Q4 2019.

  • Quarterly Long-Term Deferred Tax fell 99.01% to $218000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $218000.0 through Dec 2019, down 99.01% year-over-year, with the annual reading at $218000.0 for FY2019, 99.01% down from the prior year.
  • Long-Term Deferred Tax for Q4 2019 was $218000.0 at Niagen Bioscience, down from $22.1 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $22.1 million in Q4 2018, with the low at $144000.0 in Q4 2017.
  • Average Long-Term Deferred Tax over 4 years is $7.7 million, with a median of $399000.0 recorded in 2016.
  • The sharpest move saw Long-Term Deferred Tax surged 15225.69% in 2018, then plummeted 99.01% in 2019.
  • Over 4 years, Long-Term Deferred Tax stood at $399000.0 in 2016, then crashed by 63.91% to $144000.0 in 2017, then soared by 15225.69% to $22.1 million in 2018, then tumbled by 99.01% to $218000.0 in 2019.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $218000.0, $22.1 million, and $144000.0 for Q4 2019, Q4 2018, and Q4 2017 respectively.